256 related articles for article (PubMed ID: 24274365)
21. Impulse control disorders in patients with dopamine agonist-treated pituitary adenomas: a cross-sectional multicenter study.
Almalki MH; Alsuraikh MA; Almalki E; Aziz F; Almazrouei R; AlDahmani KM; Alshahrani F; Alaqeel M; Mahzari M; Ekhzaimy A
Pituitary; 2024 Apr; 27(2):197-203. PubMed ID: 38345719
[TBL] [Abstract][Full Text] [Related]
22. Effect of Dopaminergic Therapy on Impulse Control Disorders in Patients With a Prolactinoma.
Ozdeniz Varan E; Gurvit H
Cogn Behav Neurol; 2023 Mar; 36(1):1-8. PubMed ID: 36149404
[TBL] [Abstract][Full Text] [Related]
23. A European multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short- and long-acting dopamine agonists.
Rizos A; Sauerbier A; Antonini A; Weintraub D; Martinez-Martin P; Kessel B; Henriksen T; Falup-Pecurariu C; Silverdale M; Durner G; Røkenes Karlsen K; Grilo M; Odin P; Chaudhuri KR;
Eur J Neurol; 2016 Aug; 23(8):1255-61. PubMed ID: 27170229
[TBL] [Abstract][Full Text] [Related]
24. Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study.
Cornelius JR; Tippmann-Peikert M; Slocumb NL; Frerichs CF; Silber MH
Sleep; 2010 Jan; 33(1):81-7. PubMed ID: 20120624
[TBL] [Abstract][Full Text] [Related]
25. A Genetic Assessment of Dopamine Agonist-Induced Impulse Control Disorder in Patients With Prolactinoma.
Sahin S; Sudutan T; Kavla Y; Durcan E; Özogul YY; Poyraz BC; Sayitoglu M; Ozkaya HM; Kadioglu P
J Clin Endocrinol Metab; 2023 May; 108(6):e275-e282. PubMed ID: 36494095
[TBL] [Abstract][Full Text] [Related]
26. Dopamine D2 receptor imaging in pituitary adenomas using iodine-123-epidepride and SPECT.
Pirker W; Riedl M; Luger A; Czech T; Rössler K; Asenbaum S; Angelberger P; Kornhuber J; Deecke L; Podreka I; Brücke T
J Nucl Med; 1996 Dec; 37(12):1931-7. PubMed ID: 8970508
[TBL] [Abstract][Full Text] [Related]
27. Impulse control disorders in Parkinson disease: A cross-sectional study in Morocco.
El Otmani H; Mouni FZ; Abdulhakeem Z; Attar Z; Rashad L; Saali I; El Moutawakil B; Rafai MA; Slassi I; Nadifi S
Rev Neurol (Paris); 2019 Apr; 175(4):233-237. PubMed ID: 30935674
[TBL] [Abstract][Full Text] [Related]
28. Radiographic and Hormonal Regression in Prolactinomas: An Analysis of Treatment Failure.
Akinduro OO; Lu VM; Izzo A; De Biase G; Vilanilam G; Van Gompel JJ; Bernet V; Donaldson A; Olomu O; Meyer FB; Quinones-Hinojosa A; Chaichana KL
World Neurosurg; 2019 Sep; 129():e686-e694. PubMed ID: 31181361
[TBL] [Abstract][Full Text] [Related]
29. [Impulsive-compulsive syndrome in Parkinson's disease].
Nikitina AV; Fedorova NV
Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(7 Pt 2):32-8. PubMed ID: 23994929
[TBL] [Abstract][Full Text] [Related]
30. Treatment of impulse control disorders in Parkinson's disease: Practical considerations and future directions.
Ramirez-Zamora A; Gee L; Boyd J; Biller J
Expert Rev Neurother; 2016; 16(4):389-99. PubMed ID: 26923084
[TBL] [Abstract][Full Text] [Related]
31. Mucocele-like formation leading to neurological symptoms in prolactin-secreting pituitary adenomas under dopamine agonist therapy.
Abe T; Lüdecke DK
Surg Neurol; 1999 Sep; 52(3):274-9. PubMed ID: 10511086
[TBL] [Abstract][Full Text] [Related]
32. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma.
Kars M; Delgado V; Holman ER; Feelders RA; Smit JW; Romijn JA; Bax JJ; Pereira AM
J Clin Endocrinol Metab; 2008 Sep; 93(9):3348-56. PubMed ID: 18559921
[TBL] [Abstract][Full Text] [Related]
33. Predictors of dopamine agonist resistance in prolactinoma patients.
Vermeulen E; D'Haens J; Stadnik T; Unuane D; Barbe K; Van Velthoven V; Gläsker S
BMC Endocr Disord; 2020 May; 20(1):68. PubMed ID: 32429916
[TBL] [Abstract][Full Text] [Related]
34. The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy.
Soule SG; Farhi J; Conway GS; Jacobs HS; Powell M
Clin Endocrinol (Oxf); 1996 Jun; 44(6):711-6. PubMed ID: 8759184
[TBL] [Abstract][Full Text] [Related]
35. Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms.
Pivonello C; Patalano R; Negri M; Pirchio R; Colao A; Pivonello R; Auriemma RS
Front Endocrinol (Lausanne); 2021; 12():791633. PubMed ID: 35095761
[TBL] [Abstract][Full Text] [Related]
36. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
[TBL] [Abstract][Full Text] [Related]
37. Current approach to treatments for prolactinomas.
Tirosh A; Shimon I
Minerva Endocrinol; 2016 Sep; 41(3):316-23. PubMed ID: 26399371
[TBL] [Abstract][Full Text] [Related]
38. Diagnosis and drug therapy of prolactinoma.
Ciccarelli E; Camanni F
Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
[TBL] [Abstract][Full Text] [Related]
39. The Role of Dopamine Agonists in Pituitary Adenomas.
Giraldi EA; Ioachimescu AG
Endocrinol Metab Clin North Am; 2020 Sep; 49(3):453-474. PubMed ID: 32741482
[TBL] [Abstract][Full Text] [Related]
40. 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas.
Andereggen L; Frey J; Andres RH; El-Koussy M; Beck J; Seiler RW; Christ E
Endocrine; 2017 Jan; 55(1):223-230. PubMed ID: 27688009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]